Loading...
NPI 1477602639 · Santa Barbara, CA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Pacific Diagnostic Laboratories is a clinical medical laboratory provider located in Santa Barbara, California. This profile covers 271 Medicare and 239 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Pacific Diagnostic Laboratories |
| Address | 454 S Patterson Ave |
| City | Santa Barbara |
| State | CA |
| ZIP | 93111 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | January 9, 2007 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $19.7M |
| Medicare | $9.8M |
Payer mix and scale: This lab reports lifetime Medicare revenue of $9.8M and lifetime Medicaid revenue of $19.7M, with Medicaid representing the larger source of public-payer dollars on file. The disparity in scale indicates the organization operates with substantial engagement in the Medicaid market while maintaining a meaningful Medicare footprint.
Medicare revenue concentration: The top three Medicare codes account for 30.9% of the provider's Medicare revenue, concentrated in high-volume collection and routine chemistry testing: 36415 ($813.1K, 11.8% of Medicare revenue), 80053 ($707.1K, 10.2%), and 84443 ($613K, 8.9%). This concentration signals that phlebotomy/collection services and standard panels (CMP and TSH) are principal drivers of Medicare billing.
Medicaid revenue concentration: The top three Medicaid codes account for 27.1% of the provider's Medicaid revenue and are led by U0003 ($1.8M, 13.2% of Medicaid revenue), 80053 ($973.6K, 7.0%), and 84443 ($962.6K, 6.9%). High Medicaid share for U0003 alongside large CMP and TSH volumes indicates substantial billing for SARS-CoV-2 molecular testing plus the same routine panel work that drives Medicare revenue.
Service-line profile: The mix of high-volume codes (36415, 80053, 85025, 83036, 82306) combined with substantive pathology and cytology entries (88305, 88307, 88175, 88341) shows this entity operates as a full-service clinical laboratory with both high-throughput diagnostic chemistry/hematology and a developed anatomic/cytopathology capability. Medicaid-specific codes such as 86003 (allergen IgE) and 87491/87591 (chlamydia and GC NAAT) further indicate a broader molecular and specialty-testing portfolio in-state.
National competitive standing (Medicare): PACIFIC DIAGNOSTIC LABORATORIES ranks as a national outlier on multiple common laboratory services — for example, 36415 ranks #42 of 86467 providers nationally (100th percentile; extreme outlier), 80053 ranks #56 of 26416 (100th percentile; extreme outlier), and 84443 ranks #52 of 19722 (100th percentile; extreme outlier). These rank/percentile labels identify the provider as a dominant national volume performer for basic collection and routine panel testing.
State competitive standing (Medicaid): In California Medicaid data the provider shows a strong statewide presence but with more typical in-state percentiles for high-revenue items; examples include U0003 at 29.4K claims/$1.8M revenue (ranks #57 of 751 in-state, 93rd percentile; typical, unremarkable), 80053 at $973.6K (ranks #36 of 1717, 98th percentile), and 84443 at $962.6K (ranks #18 of 1360, 99th percentile). These placements indicate the lab is a major state-level performer across panels and molecular testing but not universally an extreme outlier in the Medicaid market.
Tenure and scale implication: The provider's NPI was enumerated on 2007-01-09 (~19 years ago), and the combination of long tenure with lifetime public-payer receipts of $9.8M (Medicare) and $19.7M (Medicaid) supports the interpretation of an established regional laboratory operation with sustained volume across multiple testing modalities. This longevity aligns with the broad code mix spanning routine chemistry, molecular, immunology, and pathology.
Statistical standing nuance for analysts: Several Medicare codes are labeled "extreme outlier" or at the 100th percentile (e.g., 36415, 80053, 84443, 82306, 85025), while many high-revenue Medicaid codes are described as "typical, unremarkable" or high-percentile but not extreme (e.g., U0003 93rd, 80053 98th, 84443 99th). Analysts should note this contrast—nationally the provider posts outsized volumes on fundamental lab services, whereas in-state Medicaid volumes are large but generally align with other high-volume California labs for similar codes.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
271 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 101,640 | $10 | $813.1K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 70,710 | $10 | $707.1K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 38,320 | $20 | $613K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 21,080 | $30 | $611.4K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 67,400 | $10 | $539.2K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 39,520 | $10 | $513.7K |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 9,290 | $60 | $510.9K |
| 83036 | Sugar in the bloodstream can get attached to the hemoglobin in red blood cells. Once the sugar is attached, it stays there for the lifetime of the red blood cell (around 120 days or over 3 months).… | 28,270 | $10 | $282.7K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 3,330 | $70 | $246.7K |
| 82607 | The lab analyst performs a test to measure the amount of vitamin B12 in a patient specimen, typically in patient blood. | 14,880 | $20 | $223.3K |
Showing 1–10 of 271
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 271 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
271 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| U0003 | 28 | 130 | 730 | $70 | $246.4K |
| 88185 | 5 | 40 | 1,560 | $20 | $139.2K |
| G0480 | 32 | 50 | 70 | $110 | $119.4K |
| G2023 | 23 | 90 | 1,030 | $20 | $110.9K |
| G0471 | 6 | 10 | 2,960 | $10 | $94.2K |
| 86235 | 10 | 60 | 1,220 | $20 | $75.7K |
| U0005 | 31 | 150 | 780 | $20 | $75.1K |
| 87481 | 76 | 100 | 270 | $30 | $72.7K |
| 87636 | 55 | 90 | 40 | $140 | $70.6K |
| 80307 | 87 | 150 | 220 | $60 | $69.2K |
Showing 1–10 of 271
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
239 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 29,440 | $60 | $1.8M |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 139,090 | $10 | $973.6K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 80,210 | $10 | $962.6K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 49,090 | $20 | $932.8K |
| 88175 | The lab analyst performs the technical lab test to analyze a cervical or vaginal cytopathology specimen that a clinician collected in preservative fluid. The test uses automated thin layer… | 41,480 | $20 | $912.5K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 29,660 | $30 | $860.1K |
| 86003 | The lab analyst performs the technical lab test to analyze a specimen such as serum for allergen–specific immunoglobulin E (IgE), using a crude allergen extract. The test result is quantitative or… | 8,050 | $100 | $829.4K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 29,530 | $30 | $826.8K |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 10,510 | $70 | $767K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 72,610 | $10 | $653.4K |
Showing 1–10 of 239
How this provider's Medicaid billing volume and revenue compare to other California providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. California median
239 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 63 | 70 | 650 | $70 | $1.6M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 57 | 750 | 950 | $50 | $890K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 229 | 660 | 1,490 | $30 | $417.2K |
| 99199 | Use this code to report other medicine services or procedures for which there is no specific code available. | 218 | 410 | 1,130 | $70 | $372K |
| 88185 | The lab analyst performs the technical component of a flow cytometry procedure using cell surface, cytoplasmic, or nuclear markers to characterize cells and aid clinicians in diagnosing patients with… | 36 | 40 | 220 | $140 | $354.7K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 98 | 340 | 970 | $40 | $343.6K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 211 | 280 | 730 | $90 | $315.5K |
| 81513 | The lab analyst performs the technical lab test on a vaginal fluid specimen for quantitative real–time amplification of RNA markers for three bacterial species listed in the code descriptor, and… | 28 | 50 | 670 | $40 | $282.6K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 189 | 290 | 220 | $210 | $268.3K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 48 | 1,140 | 530 | $20 | $195.6K |
Showing 1–10 of 239
Other providers in the same ZIP code as Pacific Diagnostic Laboratories, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Robert Leposavic | CA | MOHS-Micrographic Surgery Physician | $1.2M | $0 |
| Joseph Garofalo | CA | Podiatrist | $282.6K | $192.7K |
| Thomas Vanmeter | CA | Dermatology Physician | $407.4K | $0 |
| Salvatore Garofalo | CA | Foot & Ankle Surgery Podiatrist | $342.8K | $0 |
| Rebecca Miller | CA | Dermatology Physician | $204.4K | $0 |
| John Mccaffery | CA | Otolaryngology Physician | $201K | $0 |
| Matthew Pifer | CA | Sports Medicine (Orthopaedic Surgery) Physician | $152K | $0 |
| Kent Funk | CA | Anesthesiology Physician | $52.4K | $0 |
| Allegra Lobell | CA | Anesthesiology Physician | $37.9K | $0 |
| Elizabeth Kim | CA | Family Medicine Physician | $26.9K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.